Correction: Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells (Journal of Hematology and Oncology (2015) 8 (41) DOI: 10.1186/s13045-015-0137-1);Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Zhao, Kai ^a   Zhou, Yuxin ^a   Qiao, Chen ^a   Ni, Ting ^a   Li, Zhiyu ^a   Wang, Xiaotang ^b   Guo, Qinglong ^a   Lu, Na ^a   Wei, Libin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Glycolysis; MDM2; Oroxylin A; PTEN; SIRT3

Indexed keywords

ESTRADIOL; FLUOROURACIL; LACTIC ACID; OROXYLIN A; PACLITAXEL; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2; PROTEIN P53; RNA; SIRTUIN 3; 5,7-DIHYDROXY-6-METHOXY-2-PHENYLCHROMEN-4-ONE; ANTINEOPLASTIC AGENT; FLAVONOID; MDM2 PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; SIRT3 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DEACETYLATION; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE TRANSPORT; GLYCOLYSIS; H1299 CANCER CELL; HCT116 CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; MCF 7 CELL LINE; MDM2 GENE; MOUSE; NONHUMAN; ONCOGENE; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN STABILITY; REGULATORY MECHANISM; UPREGULATION; ANIMAL; CONFOCAL MICROSCOPY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; NEOPLASM; NUDE MOUSE; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIRTUIN 3; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928813816     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-019-0792-8     Document Type: Erratum

References (51)

1. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413-31.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-10.
3. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-31.
4. Puzio-Kuter AM. The role of p53 in metabolic regulation. Genes Cancer. 2011;2:385-91.
5. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004;64:2627-33.
6. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126:107-20.
7. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science. 2006;312:1650-3.
8. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005;65:177-85.
9. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindstrom MS, et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell. 2007;12:355-66.
10. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol. 2001;13:332-7.
11. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007;26:5489-504.
12. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010;17:41-52.
13. Scher MB, Vaquero A, Reinberg D. SirT3 is a nuclear NAD∈+∈-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev. 2007;21:920-8.
14. Wei L, Zhou Y, Dai Q, Qiao C, Zhao L, Hui H, et al. Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma. Cell Death Dis. 2013;4:e601.
15. Qiao C, Wei L, Dai Q, Zhou Y, Yin Q, Li Z, et al. UCP2-related mitochondrial pathway participates in oroxylin A-induced apoptosis in human colon cancer cells. J Cell Physiol. 2015;230:1054-63.
16. Ha J, Zhao L, Zhao Q, Yao J, Zhu BB, Lu N, et al. Oroxylin A improves the sensitivity of HT-29 human colon cancer cells to 5-FU through modulation of the COX-2 signaling pathway. Biochem Cell Biol. 2012;90:521-31.
17. Mu R, Qi Q, Gu H, Wang J, Yang Y, Rong J, et al. Involvement of p53 in oroxylin A-induced apoptosis in cancer cells. Mol Carcinog. 2009;48:1159-69.
18. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001;98:11598-603.
19. Zhang YY, Zhou LM. Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation. Biochem Biophys Res Commun. 2012;423:26-31.
20. Chang CJ, Freeman DJ, Wu H. PTEN regulates Mdm2 expression through the P1 promoter. J Biol Chem. 2004;279:29841-8.
21. Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. SIRT3 and cancer: tumor promoter or suppressor? Biochim Biophys Acta. 2011;1816:80-8.
22. Ikenoue T, Inoki K, Zhao B, Guan KL. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res. 2008;68:6908-12.
23. Aaltonen N, Lehtonen M, Varonen K, Goterris GA, Laitinen JT. Lipid phosphate phosphatase inhibitors locally amplify lysophosphatidic acid LPA1 receptor signalling in rat brain cryosections without affecting global LPA degradation. BMC Pharmacol. 2012;12:7.
24. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008;13:454-63.
25. Ortega-Molina A, Serrano M. PTEN in cancer, metabolism, and aging. Trends Endocrinol Metab. 2013;24:184-9.
26. Shen L, Sun X, Fu Z, Yang G, Li J, Yao L. The fundamental role of the p53 pathway in tumor metabolism and its implication in tumor therapy. Clin Cancer Res. 2012;18:1561-7.
27. Zawacka-Pankau J, Grinkevich VV, Hunten S, Nikulenkov F, Gluch A, Li H, et al. Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem. 2011;286:41600-15.
28. Elison JR, Cobrinik D, Claros N, Abramson DH, Lee TC. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch Ophthalmol. 2006;124:1269-75.
29. Lu C, El-Deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis. 2009;14:597-606.
30. Yang ZX, Wang D, Wang G, Zhang QH, Liu JM, Peng P, et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:625-30.
31. Bertheau P, Espie M, Turpin E, Lehmann J, Plassa LF, Varna M, et al. TP53 status and response to chemotherapy in breast cancer. Pathobiology. 2008;75:132-9.
32. Li HN, Nie FF, Liu W, Dai QS, Lu N, Qi Q, et al. Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo. Toxicology. 2009;257:80-5.
33. Yang Y, Hu Y, Gu HY, Lu N, Liu W, Qi Q, et al. Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells. J Pharm Pharmacol. 2008;60:1459-63.
34. Gao Y, Lu N, Ling Y, Chen Y, Wang L, Zhao Q, et al. Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation. J Cancer Res Clin Oncol. 2010;136:667-75.
35. Sun Y, Lu N, Ling Y, Gao Y, Chen Y, Wang L, et al. Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Eur J Pharmacol. 2009;603:22-8.
36. Yang HY, Zhao L, Yang Z, Zhao Q, Qiang L, Ha J, et al. Oroxylin A reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-kappaB signaling pathway. Mol Carcinog. 2012;51:185-95.
37. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol. 2003;15:164-71.
38. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 2001;20:1331-40.
39. Yi J, Luo J. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta. 2010;1804:1684-9.
40. Wang X, Taplick J, Geva N, Oren M. Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett. 2004;561:195-201.
41. Juven T, Barak Y, Zauberman A, George DL, Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene. 1993;8:3411-6.
42. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res. 1995;23:2584-92.
43. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003;3:117-30.
44. Zhou M, Gu L, Findley HW, Jiang R, Woods WG. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res. 2003;63:6357-62.
45. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A. 1998;95:13513-8.
46. Cooper HM, Spelbrink JN. The human SIRT3 protein deacetylase is exclusively mitochondrial. Biochem J. 2008;411:279-85.
47. Bao J, Lu Z, Joseph JJ, Carabenciov D, Dimond CC, Pang L, et al. Characterization of the murine SIRT3 mitochondrial localization sequence and comparison of mitochondrial enrichment and deacetylase activity of long and short SIRT3 isoforms. J Cell Biochem. 2010;110:238-47.
48. Iwahara T, Bonasio R, Narendra V, Reinberg D. SIRT3 functions in the nucleus in the control of stress-related gene expression. Mol Cell Biol. 2012;32:5022-34.
49. Dai Q, Yin Y, Liu W, Wei L, Zhou Y, Li Z, et al. Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells. Int J Biochem Cell Biol. 2013;45:1468-78.
50. Li HB, Chen F. Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. J Chromatogr A. 2005;1074:107-10.
51. Zhao L, Guo QL, You QD, Wu ZQ, Gu HY. Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol Pharm Bull. 2004;27:998-1003.